In vivo CRISPR screens reveal potent driver mutations in head and neck cancers.
Sampath Kumar LoganathanDaniel SchramekPublished in: Molecular & cellular oncology (2020)
We have recently tested the transforming potential of 484 'long-tail' genes, which are recurrently albeit infrequently mutated in head and neck cancers (HNSCC). We identified 15 novel tumor suppressors and our top hits converge on regulating the NOTCH signaling pathway. Therapeutic approaches activating NOTCH signaling could be a promising strategy to treat two-thirds of human HNSCC patients.
Keyphrases
- genome wide
- signaling pathway
- end stage renal disease
- endothelial cells
- chronic kidney disease
- newly diagnosed
- ejection fraction
- dna methylation
- peritoneal dialysis
- prognostic factors
- crispr cas
- pi k akt
- high throughput
- cell proliferation
- epithelial mesenchymal transition
- gene expression
- patient reported outcomes
- risk assessment
- patient reported
- endoplasmic reticulum stress